Ocular Therapeutix (OCUL) FCF Margin (2014 - 2026)
Ocular Therapeutix (OCUL) recorded quarterly FCF Margin of 624.2% in Q1 2026, down 78.82% quarter-over-quarter from 349.07% in Q4 2025, and down 18857.0% on a YoY basis from N/an in Q1 2025.
Ocular Therapeutix (OCUL) FCF Margin (2014 - 2026) Analysis & Trends
Ocular Therapeutix's FCF Margin history runs 13 years deep, the most recent figure standing at 624.2% for Q1 2026.
- In Q1 2026, FCF Margin fell 18857.0% year-over-year to 624.2%; the TTM figure through Mar 2026 stood at 435.78% (down 18889.0% YoY), while the FY2025 annual figure was 396.64%, down 18510.0% from the prior year.
- FCF Margin was 624.2% for Q1 2026 at Ocular Therapeutix, down from 349.07% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 52.99% in Q3 2023 to a low of 624.2% in Q1 2026.
- Historically, FCF Margin has averaged 237.55% across 5 years, with a median of 163.3% in 2023.
- The sharpest annual moves came in 2022 and 2025: FCF Margin surged 9343 bps in 2022, then tumbled 26430 bps in 2025.
- A 5-year view of FCF Margin shows it stood at 143.49% in 2022, then grew by 21 bps to 113.79% in 2023, then slumped by 103 bps to 231.09% in 2024, then plunged by 51 bps to 349.07% in 2025, then plunged by 79 bps to 624.2% in 2026.
- The last three FCF Margin figures came in at 624.2% (Q1 2026), 349.07% (Q4 2025), and 389.98% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ocular Therapeutix | 2.12 Bn | 2.12 Bn | 9.46 Mn | -624.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -624.20% |
| Dec 31, 2025 | -349.07% |
| Sep 30, 2025 | -389.98% |
| Jun 30, 2025 | -419.67% |
| Mar 31, 2025 | -435.63% |
| Dec 31, 2024 | -231.09% |
| Sep 30, 2024 | -231.04% |
| Jun 30, 2024 | -155.37% |
| Mar 31, 2024 | -231.10% |
| Dec 31, 2023 | -113.79% |
| Sep 30, 2023 | -52.99% |
| Jun 30, 2023 | -163.30% |
| Mar 31, 2023 | -154.17% |
| Dec 31, 2022 | -143.49% |
| Sep 30, 2022 | -112.00% |
| Jun 30, 2022 | -88.42% |
| Mar 31, 2022 | -143.14% |
| Dec 31, 2021 | -128.24% |
| Sep 30, 2021 | -111.39% |
| Jun 30, 2021 | -171.14% |